OKLAHOMA CITY--(BUSINESS WIRE)--InterGenetics®, a personalized medicine company focused on molecular diagnostics and targeted therapy for cancer, announced the addition of fourteen new clinical sites in nine new states for the distribution of OncoVue, the first broadly applicable genetics-based breast cancer risk test. OncoVue incorporates both gene-based information and personal history measures to determine a woman’s future risk of developing breast cancer.
